

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Trademark, DC 20231.

COPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 149B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete If Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	✓	MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361	
	✓	CLARK, K, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	
	✓	CHEUNG, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
	✓	DERIVENT ABSTRACT, 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhesion molecule expression (Eng.)", 1996	
TNT	✓	DERIVENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating arteriosclerosis", 1993	
		DERIVENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto-immune diseases, etc."	
		DERIVENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs. - are orally administered antitumour agents without side effects of parent"	
TNT	✓	KALIA, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfate-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900	
	✓	KALIA, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-allyl-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498	
	✓	KALIA, Von R., et al, "Identifizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,5-diethyl-6-chlorouracil und Bildungsmechanismus der SCH - Metaboliten", Arzneimittel-Forsch./Drug Res., 1982; 32(1)(6); pp 610-612	
TNT	✓	BRENNAN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1979; pp 2385-2391	

RECEIVED

AUG 01 2002

OFFICE OF PETITIONS

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/088 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	✓	PECORARI, Piergiorgio, et al, "Synthesis And Biological Activity of Pyrimido [2,1-b] [1,3]Thiazine, [1,3]Thiazino[3,2-a]Purine And [1,2,3]Triazolo[4,5-d][1,3]Thiazino[3,2-a]Pyrimidine Derivatives And Thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
	✓	DE MELO, S. J., et al, "5-flouro (3H) pyrimidine-4-ones: synthese, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques francaises, 1992, 50, n 1, pp 39-51	
	✓	Chem. Abstr. 1992; 117; pp 143023c - COPY TO FOLLOW	
	✓	PASKHUTDINOW, et al, Kim. Farm. Zh. 1988; 22(5); pp 557 - COPY TO FOLLOW	
		Chem. Abstr. 1988; 109; pp 162901r - COPY TO FOLLOW	
TNT	✓	TOZKOPARAN, Birsen, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331, (Weinheim, Germany); 1998; pp 201-206	

RECEIVED

AUG 01 2002

OFFICE OF PETITIONS

Examiner Signature

[Signature]

Date Considered

5/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361	
		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	
		CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
		DERWENT ABSTRACT, 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhesion molecule expression (Eng.)"	
		DERWENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating arteriosclerosis"	
		DERWENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto-immune diseases, etc."	
		DERWENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs. - are orally administered antitumour agents without side effects of parent"	
		KAUL, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900	
		KAUL, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-allyl-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498	
		KAUL, Von R., et al, "Identifizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", Arzneim./Forsch./Drug Res., 1982; 32(1)(6); pp 610-612	
		BROWN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1972; pp 2385-2391	

Duplicate
of
Super #5

Examiner Signature		Date Considered	5/12/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PECORARI, Piergiorgio, et al, "Synthesis And Biological Activity of Pyrimido [2,1-b] [1,3]Thiazine, [1,3]Thiazino[3,2-a]Purine And [1,2,3]Triazolo[4,5-d][1,3]Thiazino[3,2-a]Pyrimidine Derivatives And Thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
		DE MELO, S. J., et al, "5-flouro (3H) pyrimidine-4-ones: synthese, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques francaises, 1992, 50, n 1, pp 39-51	
		Chem. Abstr. 1992; 117; pp 143023e - COPY TO FOLLOW	
		FASKHUTDINOW, et al, Kim. Farm. Zh. 1988; 22(5); pp 557 - COPY TO FOLLOW	
		Chem. Abstr. 1988; 109; pp 162901r - COPY TO FOLLOW	
		TOZKOPARAN, Birsen, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331, (Weinheim, Germany); 1998; pp 201-206	

Examiner
Signature

[Signature]

Date

Considered

5/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FORM PTO-1449
(Rev. 2-32)

U.S. DEPARTMENT OF
COMMERCE PATENT AND
TRADEMARK OFFICE

ATTY. DOCKET NO.
A0000425-01-CFP

SERIAL NO.
10/071,032

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Richard Dennis Dyer, et al.

FILING DATE
February 08, 2002

**GROUP
1624**

TECH CENTER 1800129000
JUL 3 2000

JUL 30 2003

RECEIVED
2003

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

[illegible]

EXAMINER

Ullmann

DATE CONSIDERED

5/12/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.